certolizumab pegol
Cimzia (certolizumab pegol) is a PEGylated antibody fragment from UCB that neutralises TNF-alpha. Without the Fc portion, it is designed to calm inflammation in rheumatoid arthritis and Crohn disease while behaving differently from full-length antibodies.
This page is based on FDA prescribing information and the EMA medicine record for certolizumab pegol, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Inflammatory disease keeps sounding a TNF-alpha alarm that calls more immune cells to the scene. Cimzia is a small, long-lasting catcher shaped for the alarm signal itself. It mops up the alarm before it spreads, and because it lacks the usual antibody tail, it does little more than catch - no extra calls for backup.
In simple terms
TNF-alpha is one of the main chemical messengers that keep inflammation going in rheumatoid arthritis and Crohn disease. Certolizumab pegol is an antibody fragment that binds TNF-alpha and neutralises it. Unlike full antibodies, it is built without the Fc tail and is linked to polyethylene glycol, which prolongs its action. With less TNF-alpha signalling, pain, swelling and tissue damage are reduced.
In depth
Certolizumab pegol is a PEGylated Fab fragment of a humanised anti-TNF-alpha monoclonal antibody. It neutralises soluble and membrane-bound TNF-alpha by blocking receptor binding. The absence of an Fc region means it does not fix complement or trigger antibody-dependent cellular cytotoxicity, and 40 kDa PEG conjugation extends plasma half-life. These properties distinguish it pharmacologically from full-length anti-TNF antibodies such as infliximab and adalimumab.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How TNF-alpha inhibitors work
- TNF-alpha is one of the main chemical messengers that keep inflammation going in rheumatoid arthritis and Crohn disease.
- Certolizumab pegol binds TNF-alpha and neutralises it, so the cytokine cannot reach its receptor.
- It carries no Fc region, so it does little more than catch TNF-alpha - no extra calls for immune backup.
- With less TNF-alpha signalling, pain, swelling and tissue damage are reduced.
Target: Tumour necrosis factor alpha (TNF-alpha)
A pro-inflammatory cytokine that sustains joint and gut inflammation in diseases such as rheumatoid arthritis and Crohn disease; neutralising it lets inflamed tissue settle.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Reducing signs and symptoms of Crohn disease and maintaining clinical response in adults with moderately to severely active disease who have had an inadequate response to conventional therapy
- Treatment of adults with moderately to severely active rheumatoid arthritis
- Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
Approved uses in European Union
EMA- With methotrexate, for moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drugs has been inadequate, or as monotherapy when methotrexate is inappropriate
- With methotrexate, for severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate
Official sources
The statements on this page trace back to these records.
- DailyMed: Cimzia (certolizumab pegol) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: certolizumab pegol prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: certolizumab pegol
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.